Candel Therapeutics Inc (CADL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Candel Therapeutics Inc (CADL) has a cash flow conversion efficiency ratio of -0.131x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-18.04 Million) by net assets ($138.03 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Candel Therapeutics Inc balance sheet independence to measure how much of total assets are equity-financed.
Candel Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Candel Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check CADL cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Candel Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Candel Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Xiangyang Automobile Bearing Co Ltd
SHE:000678
|
0.094x |
|
NORVA24 GROUP AB (PUBL.)
F:WG0
|
N/A |
|
Henan Newland Pharmaceutical Co. Ltd. A
SHE:301277
|
N/A |
|
Shenzhen MinDe Electronics Technology Ltd
SHE:300656
|
0.020x |
|
Hingham Institution for Savings
NASDAQ:HIFS
|
0.023x |
|
Skandinaviska Enskilda Banken AB (publ)
ST:SEB-C
|
1.189x |
|
Zhejiang Yankon Group Co Ltd
SHG:600261
|
0.022x |
|
Shandong Jinling Mining Co Ltd
SHE:000655
|
0.023x |
Annual Cash Flow Conversion Efficiency for Candel Therapeutics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Candel Therapeutics Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see Candel Therapeutics Inc (CADL) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $51.92 Million | $-38.31 Million | -0.738x | -81.10% |
| 2024-12-31 | $66.33 Million | $-27.02 Million | -0.407x | +84.84% |
| 2023-12-31 | $12.74 Million | $-34.24 Million | -2.687x | -308.04% |
| 2022-12-31 | $47.71 Million | $-31.42 Million | -0.658x | -90.09% |
| 2021-12-31 | $64.14 Million | $-22.22 Million | -0.346x | -189.98% |
| 2020-12-31 | $-23.56 Million | $-9.07 Million | 0.385x | -40.23% |
| 2019-12-31 | $-8.04 Million | $-5.18 Million | 0.644x | -- |
About Candel Therapeutics Inc
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of … Read more